Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
28 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
MARC-PHARMA from Walcourt, company number BE1017943140, closed financial year 2025 with a result of € 16,193 after tax. For that financial year MARC-PHARMA recorded a gross margin of € 23,605 and equity of € 21,193. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 21,193
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 16,193
Profit after tax over the fiscal year.
€ 51
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 16,193.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 774
Supplier invoices still open on the last day of the fiscal year.
€ 14,108
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to MARC-PHARMA?
What happened at MARC-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 16,193. Source: NBB ↗
- New establishment in Walcourt. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 5,115 in corporate taxes since 2025.
A new publication or filing at MARC-PHARMA? We notify you, reason included.
Follow MARC-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MARC-PHARMA is Marc-Louis FADIHERBE.
Directors
According to the 2025 annual accounts
Marc-Louis FADIHERBE
Director
Establishments
Establishment units
Physical locations of this company
Route de Philippeville(Tar) 57
5651 Walcourt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 28 companies are registered at this address.
All companies at this address →PARTNERS EXPERTISE
€ 464,725 gross margin · 2025
CHIMATEX
€ 100,850 gross margin · 2025
PROJET ROCOURT
€ -1,912 gross margin · 2025
PARTNERS FIDUCIAIRE
€ 533,058 gross margin · 2025
ASSEC-IT
€ 7,314 gross margin · 2025
+23 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1017.943.140
- VAT number
- BE 1017.943.140
- Registered office
- Route de Philippeville(Tar) 57, 5651 Walcourt
- Names & denominations
- MARC-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 December 2024
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Vervaardiging van overige farmaceutische producten
Vervaardiging van farmaceutische grondstoffen